Bedaquiline microheteroresistance after cessation of tuberculosis treatment

Simple item page
dc.contributor.authorDe Vos, Margarethaen_ZA
dc.contributor.authorWiggins, Kristin B.en_ZA
dc.contributor.authorDerendinger, Brigittaen_ZA
dc.contributor.authorReuter, Anjaen_ZA
dc.contributor.authorDolby, Taniaen_ZA
dc.contributor.authorBurns, Scotten_ZA
dc.contributor.authorSchito, Marcoen_ZA
dc.contributor.authorEngelthaler, David M.en_ZA
dc.contributor.authorMetcalfe, Johnen_ZA
dc.contributor.authorTheron, Granten_ZA
dc.contributor.authorVan Rie, Anneliesen_ZA
dc.contributor.authorPosey, Jamesen_ZA
dc.contributor.authorWarren, Roben_ZA
dc.contributor.authorCox, Helenen_ZA
dc.date.accessioned2021-10-18T10:38:17Z
dc.date.available2021-10-18T10:38:17Z
dc.date.issued2019-05-30
dc.descriptionCITATION: de Vos, M. et al. 2019. Bedaquiline microheteroresistance after cessation of tuberculosis treatment. New England Journal of Medicine, 380(22):2178-2180. doi:10.1056/NEJMc1815121
dc.descriptionThe original publication is available at https://www.nejm.org/
dc.description.abstractENGLISH ABSTRACT: Bedaquiline improves survival among persons with multidrug-resistant tuberculosis (MDR-TB).1 We report the case of a 65-year-old South African man who was negative for human immunodeficiency virus and in whom MDR-TB was diagnosed in 2013 (resistant to rifampin and isoniazid; phenotypically susceptible to a fluoroquinolone and amikacin). A baseline radiograph showed changes consistent with bilateral tuberculosis with left apex cavitation. He started standardized treatment that included moxifloxacin, pyrazinamide, kanamycin, ethionamide, isoniazid, and terizidone. After initial sputum culture conversion (at month 3) and clinical improvement, the patient again became culture-positive, and bilateral cavitation developed. After detection of phenotypic resistance to fluoroquinolones (at month 6), his treatment was revised (at month 8) to include high-dose isoniazid, ethambutol, pyrazinamide, terizidone, linezolid, paraaminosalicylic acid, and kanamycin (Figure 1 and the Supplementary Appendix, available with the full text of this letter at NEJM.org). Bedaquiline was added 22 days later and was administered for 6 months.2 The patient remained culture-positive (treatment failure), and treatment was stopped 15 months after revision of the regimen. The patient died 7 months later.en_ZA
dc.description.urihttps://www.nejm.org/doi/full/10.1056/NEJMc1815121
dc.description.versionPublisher’s version
dc.format.extent3 pagesen_ZA
dc.identifier.issn1533-4406 (online)
dc.identifier.issn0028-4793 (print)
dc.identifier.issndoi:10.1056/NEJMc1815121
dc.identifier.otherdoi:10.1056/NEJMc1815121
dc.identifier.urihttp://hdl.handle.net/10019.1/123241
dc.language.isoen_ZAen_ZA
dc.publisherMassachusetts Medical Societyen_ZA
dc.rights.holderMassachusetts Medical Societyen_ZA
dc.subjectTuberculosisen_ZA
dc.subjectBedaquiline Microheteroresistanceen_ZA
dc.subjectMultidrug-resistant tuberculosis -- Treatmenten_ZA
dc.subjectMycobacterium tuberculosisen_ZA
dc.titleBedaquiline microheteroresistance after cessation of tuberculosis treatmenten_ZA
dc.typeEditorialen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
devos_bedaquiline_2019.pdf
Size:
158.32 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Molecular Biology and Human Genetics)